Patent US5616135A successfully refreshed from Google Patents.
Patent US4866168A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4866168A Expired / Lapsed US ⏱️ 0.0 years remaining

Hematoporphyrin derivatives and process of preparing

Assignee: Health Research Inc
•
Filing: 1986-07-24
•
Granted: 1989-09-12
•
Expires: 2006-07-24
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract To obtain tumor-selective, photosensitizing drugs useful in the localization of neoplastic tissue and treatment of abnormal neoplastic tissue such as tumors, one of two methods is used. In the first method, a hydrolyzed mixture of the products of reaction of hematoporphyrin with acetic acid and sulfuric acid is cycled through a microporous membrane system to exclude low molecular weight products. In the second method, drugs are synthesized or derived from other pyrrole compounds. The drugs: (1) include two covalently bound groups, each with four rings, some of which are pyrroles such as phlorins, porphyrins, chlorins, substituted pyrroles, substituted chlorins or substituted phlorins, each group being arranged in a ring structure, connected covalently to another group and have a triplet energy state above 37.5 kilocalories per mole; (2) are soluble in water, forming an aggregate of over 10,000 molecular weight in water and have an affinity for each other compared to serum protein such that 10 to 100 percent remain self aggregated in serum protein; and (3) are lipophyllic and able to disaggregate and attach to cell plasma, nuclear membrane, mitochondria, lysosomes and tissue. The drug obtained by the first method has an empirical formula of approximately C68H70N8O11 or C68H66N8O11Na4. Neoplastic tissue retains the drug after it has cleared normal tissues and illumination results in necrosis. Moreover, other photosensitizing materials may be combined with a carrier that enters undesirable tissues and cells of the reticular endothelial system such as macrophages. These photosensitizing materials: (1) must have a triplet energy state above 3.5 kilocalories per mole; (2) cannot be easily oxidized; and (3) not physically quench any required energy state. Preferably, this photosensitizing material should be lipophlic.

Inventors

  • 👤 Thomas J. Dougherty
  • 👤 William R. Potter
  • 👤 Kenneth R. Weishaupt

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 21:42
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61B; A61B5/00; A61B5/41; A61B5/411; A61B5/414; A61B5/416; A61K41/00; A61K41/0057; A61K41/0071; A61N; A61N5/00; A61N5/06; A61N5/0601; A61N5/0613; A61N5/062; A61P; A61P35/00; A61P43/00; C; C07; C07D; C07D519/00; G; G02; G02B; G02B6/00; G02B6/24; G02B6/26; G02B6/262; G02B6/42; G02B6/4201; G02B6/4204; A61B5/0059; A61B5/0071; A61B5/0082; A61B5/0084; G02B6/4298; Y; Y10; Y10S; Y10S607/00; Y10S607/901

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 91 words
A process to prepare a composition consisting essentially of 10 kd aggregates of porphyrins which are fluorescent, photosensitizing, and capable of localizing and being retained in tumor cells for a longer time than normal tissues, which process comprises raising the pH of a hematoporphyrin derivative preparation in aqueous medium to 6.5-12 to obtain aggregates of 10 kd or greater, and separating said aggregates from the remainder of the hematoporphyrin derivative preparation, wherein hematoporphyrin derivative preparation has been prepared by treating hematoporphyrin hydrochloride with a mixture of acetic acid and sulfuric acid.
Claim 2
Dependent Claim 91 words
A process to prepare a composition consisting essentially of 10 kd aggregates of porphyrins which are fluorescent, photosensitizing, and capable of localizing and being retained in tumor cells for a longer time than normal tissues, which process comprises raising the pH of a hematoporphyrin derivative preparation in aqueous medium to 6.5-12 to obtain aggregates of 10 kd or greater, and separating said aggregates from the remainder of the hematoporphyrin derivative preparation, wherein hematoporphyrin derivative preparation has been prepared by treating hematoporphyrin hydrochloride with a mixture of acetic acid and sulfuric acid.
Claim 3
Dependent Claim 11 words
The process of claim 1 wherein the pH is approximately 9.5.
Claim 4
Dependent Claim 23 words
The process of claim 1 wherein the separation is effected by filtering in a process which retains aggregates of molecular weight above 10,000.
Claim 5
Dependent Claim 15 words
The process of claim 3 wherein the pH range of 6.5-12 is maintained during filtration.
Claim 6
Dependent Claim 15 words
The process of claim 4 wherein the pH is maintained at approximately 9.5 during filtration.
Claim 7
Dependent Claim 12 words
The process of claim 1 wherein the separation is by affinity chromatography.
Claim 8
Dependent Claim 25 words
The process of claim 6 wherein the chromatography is on a reverse phase column with a packing of 5 micron spheres, using THF as solvent.
Claim 9
Dependent Claim 42 words
The process of claim 7 wherein the reverse phase column is a C18 column and elution is successively with methanol:water:acetic acid (20:5:1) followed by tetrahydrofuran:water (4:1), and the porphyrin mixture recovered corresponds to the fourth component eluted as shown in FIG. 5.
Claim 10
Dependent Claim 54 words
The process of claim 1 wherein hematoporphyrin derivative is prepared by adding a first mixture of acetic acid and sulfuric acid to hematoporphyrin hydrochloride, stirring for one hour to obtain a second mixture, adding the second mixture to a solution of 5% soldium acetate to obtain a red precipitate, and recovering the red precipitate.
Claim 11
Dependent Claim 9 words
A composition prepared by the process of claim 1.

References Cited (Backward Citations)

US3920692A Cited
DE2809093A1 Cited
US4658023A Cited
US4614723A Cited
US4604241A Cited
US4634557A Cited
US4675338A Cited
US4656186A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1992-09-11 1993-03-13 1993-09-12 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1996-09-11 1997-03-13 1997-09-12 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2000-09-11 2001-03-13 2001-09-12 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag